Topical management of acne vulgaris using a combination gel formulation: Benzoyl peroxide 2.5%-clindamycin phosphate 1.2% gel

Expert Review of Dermatology

Volumn 5, Issue 6, 2010, Pages 597-603

  Del Rosso, James Q ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

acne vulgaris; adolescent subpopulation; benzoyl peroxide; clindamycin; combination topical acne product

Indexed keywords

BENZOYL PEROXIDE; CLINDAMYCIN;

ACNE VULGARIS; APPLICATION SITE REACTION; BURN; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GEL; HUMAN; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN IRRITATION; SKIN PENETRATION; SKIN WATER LOSS; TREATMENT OUTCOME;

EID: 78649502836     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.10.57     Document Type: Review

References (30)

1. Weinstock MA, Boyle M. Statistics of interest to the dermatologist. In: Year Book of Dermatology. Thiers BH, Lang PG (Eds). Elsevier Mosby, Philadelphia, PA, USA, 49 (2007).
2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J. Am. Acad. Dermatol. 49, S206-S210 (2003).
3. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other infammatory skin disorders: focus on antibiotic resistance. Cutis 79(Suppl. 6), 9-25 (2007).
4. Thiboutot D, Gollnick H, Bettoli V et al. Global alliance to improve outcomes in acne. J. Am. Acad. Dermatol. 60(5 Suppl.), S1-S50 (2009).
5. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from the global alliance to improve outcomes in acne. J. Am. Acad. Dermatol. 49(Suppl. 1), S1-S38 (2003
6. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol. Ther. 19, 224-236 (2006).
7. Leyden J, Kaidbey K. Levy S. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes: an in vivo comparative study. Am. J. Clin. Dermatol 2, 263-266 (2001).
8. Lookingbill DP, Chalker DK, Lindholm JS. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J. Am. Acad. Dermatol. 37, 590-595 (1997).
9. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J. Drugs Dermatol. 6, 616-622 (2007
10. Del Rosso JQ, Tanghetti E. The clinical impact of vehicle technology using a patented formulation of benzoyl peroxide 5%/clindamycin 1% gel: comparative assessments of skin tolerability and evaluation of combination use with a topical retinoid. J. Drugs Dermatol. 5, 160-164 (2006).
11. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fxed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of effcacy and safety in 2813 patients. J. Am. Acad. Dermatol. 59, 792-800 (2008).
12. Cunliffe WJ, Holland KT, Bojar R, Levy SK. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical effcacy in the topical treatment of acne vulgaris. Clin. Ther. 24, 1117-1133 (2002).
13. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization. Dermatol Clinics 27, 17-24 (2009).
14. Duac topical Gel (Siefel a GSK company Research Triangle Park, NC, USA). Prescribing information (package insert). In: Physicians' Desk Reference 2009. Thomson PDR, Montvale, NJ, USA (2009).
15. Benzaclin topical gel (Dermik Laboratories, Bridgewater, NJ, USA). Prescribing information (package insert). In: Physicians' Desk Reference 2009. Thomson PDR, Montvale, NJ, USA (2009).
16. Acanya topical gel (Coria Laboratories, Fort Worth, TX, USA). Prescribing information (package insert). In: Physicians' Desk Reference 2009. Thomson PDR, Montvale, NJ, USA (2009).
17. Thiboutot DM, Weiss J, Bucko A et al Adapalene-benzoyl peroxide, a fxed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study J. Am. Acad. Dermatol. 57, 791-799 (2007
18. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br. J Dermatol. 153, 395-403 (2005).
19. Shalita AR, Myers JA, Krochmal L, Yaroshinsky A. The safety and effcacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J. Drugs Dermatol. 4, 48-56 (2005).
20. Schlessinger J, Menter A, Gold M et al Clinical safety and effcacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J. Drugs Dermatol. 6, 607-615 (2007).
21. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J. Am. Acad. Dermatol. 54, 73-81 (2006).
22. Del Rosso JQ, Schmidt NF. A review of the anti-infammatory properties of clindamycin in the treatment of acne vulgaris. Cutis 85, 15-24 (2010).
23. Bucks D, Sarpotdar P, Yu K, Angel A, Del Rosso J. The development and optimization of a fxed combination of clindamycin and benzoyl peroxide aqeous gel. J. Drugs Dermatol. 8, 634-638 (2009).
24. Metrogel 1% topical gel (Galderma Laboratories, Fort Worth, TX, USA). Prescribing information (package insert). In: Physicians' Desk Reference 2009. Thomson PDR, Montvale, NJ, USA (2009).
25. Del Rosso J. Pharmacotherapy update: a closer look at topical metronidazole 1% gel. Skin Aging 13, 58-64 (2005).
26. Jorrizo J, Ohlrogge W, Frase T, Yu K, Chen DM, Fluhr JW A comparative, randomized, controlled, observer-blinded study to assess the skin hydration and epidermal function of 2.5% and 5% benzoyl peroxide-clindamycin topical gels (poster presentation). Presented at: Fall Clinical Dermatology. Las Vegas, NV, USA, October 16-18 (2009).
27. Gold MH. A new, once-daily, optimized, fxed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% for the treatment of mo derate-to-severe acne. J. Clin. Aesthetic Dermatol. 2, 44-48 (2009).
28. Webster G, Rich P, Gold MH, Mraz S, Calvarese B, Chen DM. Effcacy and tolerability of a fxed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J. Drugs Dermatol. 8, 736-743 (2009).
29. Cook-Bolden FE, Eichenfeld LF, Stein-Gold L, Chen DM. Managing moderate to severe acne in adolescents: benefts of a fxed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1,755 subjects (poster 740). Presented at: American Academy of Dermatology Winter Meeting. San Francisco, CA, USA, 6-10 March, 2009.
30. Kimball AB, Thiboutot DM, Chen DM, Merikle E. Impact of a fxed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel on health related quality of life in 2813 patients with moderate and severe acne vulgaris (poster presentation). Presented at: Winter Clinical Dermatology. Kauai, HI, USA, 23-28 January, 2010.